Skip to main content

Peer Review reports

From: Ipilimumab or FOLFOX with Nivolumab and Trastuzumab in previously untreated HER2-positive locally advanced or metastatic EsophagoGastric Adenocarcinoma - the randomized phase 2 INTEGA trial (AIO STO 0217)

Original Submission
12 Aug 2019 Submitted Original manuscript
5 Dec 2019 Reviewed Reviewer Report - Geoffrey Ku
23 Mar 2020 Reviewed Reviewer Report - Research Square Reviewer 1
5 Apr 2020 Author responded Author comments - Joseph Tintelnot
20 Apr 2020 Reviewed Reviewer Report - Geoffrey Ku
23 Apr 2020 Author responded Author comments - Joseph Tintelnot
Resubmission - Version 2
5 Apr 2020 Submitted Manuscript version 2
26 Apr 2020 Author responded Author comments - Joseph Tintelnot
Resubmission - Version 3
26 Apr 2020 Submitted Manuscript version 3
12 May 2020 Author responded Author comments - Joseph Tintelnot
Resubmission - Version 4
12 May 2020 Submitted Manuscript version 4
Publishing
13 May 2020 Editorially accepted
1 Jun 2020 Article published 10.1186/s12885-020-06958-3

You can find further information about peer review here.

Back to article page